Douglas Slain

4.8k total citations · 2 hit papers
48 papers, 3.2k citations indexed

About

Douglas Slain is a scholar working on Infectious Diseases, Epidemiology and Clinical Biochemistry. According to data from OpenAlex, Douglas Slain has authored 48 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Infectious Diseases, 19 papers in Epidemiology and 7 papers in Clinical Biochemistry. Recurrent topics in Douglas Slain's work include Antifungal resistance and susceptibility (13 papers), Fungal Infections and Studies (8 papers) and Antibiotic Use and Resistance (7 papers). Douglas Slain is often cited by papers focused on Antifungal resistance and susceptibility (13 papers), Fungal Infections and Studies (8 papers) and Antibiotic Use and Resistance (7 papers). Douglas Slain collaborates with scholars based in United States, China and Brazil. Douglas Slain's co-authors include E. Patchen Dellinger, Robert G. Sawyer, Maureen Bolon, Dale W. Bratzler, Trish M. Perl, Paul G. Auwaerter, Douglas N. Fish, Robert A. Weinstein, Lena M. Napolitano and Keith M. Olsen and has published in prestigious journals such as SHILAP Revista de lepidopterología, Antimicrobial Agents and Chemotherapy and Journal of Antimicrobial Chemotherapy.

In The Last Decade

Douglas Slain

48 papers receiving 3.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Clinical practice guidelines for antimicrobial prophylaxis in surgery

2013 1.5k citations Dale W. Bratzler, E. Patchen Dellinger et al. profile →
Clinical Practice Guidelines for Antimicrobial Prophylaxis in Surgery

2013 806 citations Dale W. Bratzler, E. Patchen Dellinger et al. Surgical Infections profile →

Peers

Countries citing papers authored by Douglas Slain

Since Specialization

Citations

This map shows the geographic impact of Douglas Slain's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Douglas Slain with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Douglas Slain more than expected).

Fields of papers citing papers by Douglas Slain

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Douglas Slain. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Douglas Slain. The network helps show where Douglas Slain may publish in the future.

Co-authorship network of co-authors of Douglas Slain

This figure shows the co-authorship network connecting the top 25 collaborators of Douglas Slain. A scholar is included among the top collaborators of Douglas Slain based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Douglas Slain. Douglas Slain is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Pharmacotherapeutic Considerations in the Treatment of Nontuberculous Mycobacterial Infections: A Primer for Clinicians 2024 ·Open Forum Infectious Diseases ·(unknown), Christina G. Rivera, (unknown), (unknown), Douglas Slain, Monica V. Mahoney	8
2	The prevalence of gram-negative bacteria with difficult-to-treat resistance and utilization of novel β-lactam antibiotics in the southeastern United States 2024 ·SHILAP Revista de lepidopterología ·(unknown), P. Brandon Bookstaver, Joseph Kohn, Julie Ann Justo, (unknown), (unknown), Douglas Slain, (unknown), (unknown), Bruce M Jones, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Majdi N. Al‐Hasan	1
3	Impact of clinical pharmacist discharge prescription review on the appropriateness of antibiotic therapy: a retrospective comparison 2022 ·International Journal of Clinical Pharmacy ·(unknown), (unknown), (unknown), (unknown), Douglas Slain	4
4	An Antimicrobial Treatment Assessment of Serratia marcescens Bacteremia and Endocarditis 2022 ·PubMed ·Douglas Slain, (unknown), (unknown)	7
5	Adapting the layered learning model to a virtual international exchange program 2022 ·Currents in Pharmacy Teaching and Learning ·Kazuhiko Kido, Douglas Slain, Khalid M. Kamal, James C. Lee	1
6	Plasma and Tissue Cefazolin Concentrations in Obese Patients Undergoing Cesarean Delivery and Receiving Differing Pre-Operative Doses of Drug 2013 ·Surgical Infections ·Michael L. Stitely, Michael Sweet, Douglas Slain, (unknown), (unknown), (unknown), (unknown)	43
7	Clinical Practice Guidelines for Antimicrobial Prophylaxis in Surgery breakdown → 2013 ·Surgical Infections ·Dale W. Bratzler, E. Patchen Dellinger, Keith M. Olsen, Trish M. Perl, Paul G. Auwaerter, Maureen Bolon, Douglas N. Fish, Lena M. Napolitano, Robert G. Sawyer, Douglas Slain, James P. Steinberg, Robert A. Weinstein	806
8	Eighteen cases of liver injury following ingestion of Polygonum multiflorum 2013 ·Complementary Therapies in Medicine ·Huihui Dong, Douglas Slain, Junchi Cheng, Weihang Ma, Weifeng Liang	92
9	A matched-control evaluation of an antifungal bundle in the intensive care unit at a university teaching hospital 2012 ·International Journal of Clinical Pharmacy ·Anthony J. Guarascio, Douglas Slain, (unknown), (unknown), John E. Parker, Alison Wilson, (unknown), Arif R Sarwari	31
10	Evaluation of an alternative posaconazole prophylaxis regimen in haematological malignancy patients receiving concomitant stress ulcer prophylaxis 2012 ·International Journal of Antimicrobial Agents ·(unknown), Douglas Slain, Aaron Cumpston, (unknown), Mehdi Hamadani, Michael Craig	17
11	A post-marketing evaluation of posaconazole plasma concentrations in neutropenic patients with haematological malignancy receiving posaconazole prophylaxis 2011 ·International Journal of Antimicrobial Agents ·(unknown), Douglas Slain, Aaron Cumpston, Michael Craig	51
12	Assessment of a safety enhancement to the hospital medication reconciliation process for elderly patients 2010 ·The American journal of geriatric pharmacotherapy ·(unknown), Douglas Slain, (unknown), (unknown), (unknown), (unknown)	24
13	Discrepancies between home medications listed at hospital admission and reported medical conditions 2008 ·The American journal of geriatric pharmacotherapy ·Douglas Slain, (unknown), (unknown)	14
14	Candida Endophthalmitis: Focus on Current and Future Antifungal Treatment Options 2007 ·Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy ·Fida A. Khan, Douglas Slain, Rashida Khakoo	67
15	Effect of High‐Dose Vitamin C on the Steady‐State Pharmacokinetics of the Protease Inhibitor Indinavir in Healthy Volunteers 2005 ·Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy ·Douglas Slain, (unknown), Rashida Khakoo, Melanie Fisher, David Lalka, Gerry Hobbs	35
16	An Interactive Response System to Promote Active Learning in the Doctor of Pharmacy Curriculum 2004 ·American Journal of Pharmaceutical Education ·Douglas Slain, Marie A. Abate, (unknown), Mary K. Stamatakis, (unknown)	11
17	Infrequent occurrence of amphotericin B lipid complex-associated nephrotoxicity in various clinical settings at a university hospital: A retrospective study 2002 ·Clinical Therapeutics ·Douglas Slain, (unknown), Rashida Khakoo, Melanie Fisher, (unknown), (unknown)	7
18	Metabolic Disposition and Pharmacokinetics of [¹⁴C]‐Amprenavir, a Human Immunodeficiency Virus Type 1 (HIV‐1) Protease Inhibitor, Administered As a Single Oral Dose to Healthy Male Subjects 2001 ·The Journal of Clinical Pharmacology ·Brian M. Sadler, Gregory E. Chittick, Ronald E. Polk, Douglas Slain, Thomas M. Kerkering, Scott D. Studenberg, Yu Lou, Katy H. P. Moore, Joseph L. Woolley, Daniel S. Stein	16
19	Variability in Activity of Hepatic CYP3A4 in Patients Infected with HIV 2000 ·Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy ·Douglas Slain, Amy Pakyz, Debra S. Israel, Sara Monroe, Ron E. Polk	32
20	Lipid‐Based Amphotericin B for the Treatment of Fungal Infections 1999 ·Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy ·Douglas Slain	35

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact